DOCSLIB.ORG

A Comparative Analysis of GPCR and Peptide Ligand Expression Within

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Comparative Analysis of GPCR and Peptide Ligand Expression Within This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ A comparative analysis of G-protein- coupled receptor and peptide ligand expression within human and mouse islets of Langerhans, and its application in exploring the role of CXCL14 in islet function Hawkes, Ross Graham Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 09. Oct. 2021 A comparative analysis of G-protein- coupled receptor and peptide ligand expression within human and mouse islets of Langerhans, and its application in exploring the role of CXCL14 in islet function A thesis submitted by Ross Graham Hawkes For the degree of Doctor of Philosophy from King’s College London Diabetes Research Group Division of Diabetes and Nutritional Sciences Faculty of Life Sciences and Medicine King’s College London Acknowledgements ACKNOWLEDGEMENTS I would firstly like to thank Professor Shanta Persaud and Professor Peter Jones for providing me with the opportunity to work for the Diabetes Research Group, and for creating a working environment that was perfect for undertaking a PhD in. The Diabetes Research Group at King’s College London is a unique and special place to work, and one that I will look back on fondly. An extended thank you to Professor Shanta Persaud for her guidance and support during my time at King’s, not only in relation to her supervisory role, but as someone who has lent an ear and provided sound advice in times that have required clarity and perspective. A very special thank you to Dr Stefan Amisten for the opportunity to undertake a PhD under his supervision. His patience, positivity, trust, contagious curiosity and open-mindedness have made these last years a truly interesting and enjoyable experience. I will be forever grateful to Stefan for this opportunity and look forward to celebrating over a slice of blueberry pie! In addition to my supervisors, I would also like to thank the entire Diabetes Research Group, past and present, especially Patricio Atanes, Amazon Austin, Zara Franklin, Zoheb Hassan, Robert Drynda, Alan Kerby, Ahmed Arzouni, Kerry Mclaughlin, Carolyn Johnson, Astrid Hauge-Evans, Bo Liu, Anastasia Tsakmaki, Inmaculada Ruz Maldonado, Thomas Hill and Jai David. Having fellow colleagues like these made every day that bit more enjoyable. Lastly, I would like to thank my wife Becky. Her continuous support during the ever changing course that my career has taken us on has been inspiring. Here’s to us and the future. 2 Abstract ABSTRACT G protein-coupled receptors (GPCRs) are a diverse super family of seven transmembrane spanning proteins whose primary function is to initiate the activation of intracellular signalling pathways following stimulation by extracellular stimuli, which include photons, amines, lipids, ions, peptides and proteins. Due to the ubiquitous expression of GPCRs throughout various tissues, they are implicated in the regulation of a variety of diverse physiological processes, such as secretion of the blood glucose controlling hormones insulin, glucagon and somatostatin from islets. As a result, GPCRs are being identified as therapeutic targets for the treatment of type-2 diabetes. Despite the large array of potential GPCR targets available, only a handful of GPCRs have proven to be successful clinical targets, which may partially be due to the lack of availability of suitable translational models that reflect the human GPCR landscape. The aim of the experiments described in this thesis was to compare the mRNA expression profiles of all GPCRs (the GPCRome) and all GPCR peptide ligands (the Secretome) in human and mouse islets in order to determine the suitability of using mouse islets as a translational model for predicting the role of islet GPCRs and GPCR peptide ligands in human islet function. In addition, some experiments demonstrate how the GPCRome and Secretome data were used to assess the role of CXCL14 in islet function. Quantitative real-time PCR (qPCR) was used to compare the mRNA expression profiles of 376 GPCRs and 159 GPCR peptide ligands in human islets with their orthologous counterparts in islets isolated from two strains of mice (outbred ICR mice and inbred C57/BL6 mice). A reasonable degree of similarity in GPCR mRNA expression between human islets and islets from each mouse strain was found (r2 = 0.360 vs. ICR; r2 = 0.304 vs C57), with a highly similar expression profile observed between the ICR and the C57 mouse strains (r2 = 0.946). Regression analysis of GPCR peptide ligand mRNA expression revealed that human islets exhibit a reasonable degree of similarity compared to islets of both mouse strains (r2 = 0.245 vs. ICR; r2 = 0.225 vs. C57) with a highly similar expression profile observed between the two mouse strains (r2 = 0.968). In the process of quantifying the GPCR peptide ligand mRNA expression profiles, it was revealed that the orphan chemokine CXCL14 is expressed by both mouse and human islets. Studies have shown that CXCL14 knockout mice are protected from hyperglycaemia and hyperinsulinemia and they have improved insulin sensitivity. However, CXCL14’s role in islet function has yet to be explored. The experiments described in this thesis demonstrate that CXCL14 inhibits insulin secretion from mouse islets and the MIN6 mouse β-cell line by a 3 Abstract mechanism that is not transduced through a Gαi-mediated reduction in intracellular cAMP, but is likely to occur through an inhibition of glucose uptake or glucokinase activity. Further experiments designed to elucidate the target involved in CXCL14 function revealed that CXCL14 is neither an agonist nor an antagonist for the CXCR7 receptor and the putative CXCR4 receptor, and thus these receptors are not responsible for mediating CXCL14 function. In summary, the experiments described in this thesis reveal that human and mouse islets exhibit some degree of similarity in GPCR and GPCR peptide ligand mRNA expression, but the suitability of using mouse islets as surrogates for predicting human islet physiology is receptor/receptor family specific. This thesis also reveals how the GPCRome and Secretome data can be employed to investigate the role of particular ligands, such as CXCL14, and potential GPCRs responsible for mediating the actions of such ligands in islet function. 4 Abbreviations Abbreviation Definition 18S 18S ribosomal rRNA 2DG 2-deoxy-D-glucose α Alpha Ab Antibody ATP Adenosine triphosphate β Beta bp Base pair BrdU 5-bromo-2’-deoxyuridine BSA Bovine serum albumin oC Degrees centigrade Ca2+ Calcium cAMP Cyclic adenosine 3’, 5’ - monophosphate cDNA Complementary DNA CO2 Carbon dioxide Conc. Concentration cpm Counts per minute Ct Threshold cycle CXCL12 Chemokine (C-X-C motif) ligand 12 CXCL14 Chemokine (C-X-C motif) ligand 14 dH2O Distilled water DMEM Dulbecco’s modified Eagle’s medium DMSO Dimethyl sulphoxide DNA Deoxyribonucleic acid ECM Extracellular matrix 5 Abbreviations EDTA Ethylenediaminetetraacetic acid ELISA Enzyme-linked immunosorbent assay Emax Maximum efficacy ER Endoplasmic reticulum FBS Foetal bovine serum FLIPR Fluorescent light imaging plate reader FRET Fluorescence resonance energy transfer Fura-2-AM Fura-2-acetoxymethyl derivative γ Gamma GAPDH Glyceraldehyde 3-phosphate dehydrogenase G6P Glucose-6-phosphate G6PDH Glucose-6-phosphate dehydrogenase GDP Guanosine diphosphate GLP-1 Glucagon-like peptide-1 GLUT Glucose transporter GPCR G-protein-coupled receptor Grb2 Growth factor receptor-bound protein 2 GTP Guanosine triphosphate HbA1c Glycated haemoglobin A1c HCl Hydrochloric acid Hr Hour HTRF Homogeneous time-resolved fluorescence IBMX 3-isobutyl-1-methylxanthine 6 Abbreviations INS-1 Rat insulinoma cell line IP3 Inositol 1,4,5-triphosphate IR Insulin receptor IRS Insulin receptor substrate µ Micro µg Microgram µM Micromolar mg Milligram Min Minute MIN6 Mouse insulinoma cell line mM Millimolar ml Millilitre mRNA Messenger RNA MuLVRT Murine Leukaemia Virus Reverse Transcriptase Mwt Molecular weight NaOH Sodium hydroxide NCS Newborn calf serum ng Nanogram nM Nanonmolar NSB Non-specific binding PBS Phosphate-buffered saline PCR Polymerase chain reaction PEG Polyethylene glycol PI3K Phosphatidylinositol-3-kinase 7 Abbreviations PIP2 Phosphatidylinositol 4,5-biphosphate PKA Cyclic-AMP-dependent protein kinase A PKC Protein kinase C PLA2 Phospholipase A2 PLC Phospholipase C PLD Phospholipase D PPIA
Load more

Recommended publications
  • Endothelin System and Therapeutic Application of Endothelin Receptor
    xperim ACCESS Freely available online & E en OPEN l ta a l ic P in h l a C r m f o a c l a o n l o r g u y o J Journal of ISSN: 2161-1459 Clinical & Experimental Pharmacology Research Article Endothelin System and Therapeutic Application of Endothelin Receptor Antagonists Abebe Basazn Mekuria, Zemene Demelash Kifle*, Mohammedbrhan Abdelwuhab Department of Pharmacology, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia ABSTRACT Endothelin is a 21 amino acid molecule endogenous potent vasoconstrictor peptide. Endothelin is synthesized in vascular endothelial and smooth muscle cells, as well as in neural, renal, pulmonic, and inflammatory cells. It acts through a seven transmembrane endothelin receptor A (ETA) and endothelin receptor B (ETB) receptors belongs to G protein-coupled rhodopsin-type receptor superfamily. This peptide involved in pathogenesis of cardiovascular disorder like (heart failure, arterial hypertension, myocardial infraction and atherosclerosis), renal failure, pulmonary arterial hypertension and it also involved in pathogenesis of cancer. Potentially endothelin receptor antagonist helps the treatment of the above disorder. Currently, there are a lot of trails both per-clinical and clinical on endothelin antagonist for various cardiovascular, pulmonary and cancer disorder. Some are approved by FAD for the treatment. These agents are including both selective and non-selective endothelin receptor antagonist (ETA/B). Currently, Bosentan, Ambrisentan, and Macitentan approved
    [Show full text]
  • Impaired Cellular Immunity in the Murine Neural Crest Conditional Deletion of Endothelin Receptor-B Model of Hirschsprung’S Disease
    RESEARCH ARTICLE Impaired Cellular Immunity in the Murine Neural Crest Conditional Deletion of Endothelin Receptor-B Model of Hirschsprung’s Disease Ankush Gosain1,2*, Amanda J. Barlow-Anacker1, Chris S. Erickson1, Joseph F. Pierre1, Aaron F. Heneghan1, Miles L. Epstein2, Kenneth A. Kudsk1,3 a11111 1 Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America, 2 Department of Neuroscience, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America, 3 Veteran Administration Surgical Service, William S. Middleton Memorial Veterans Hospital, Madison, United States of America * [email protected] OPEN ACCESS Citation: Gosain A, Barlow-Anacker AJ, Erickson Abstract CS, Pierre JF, Heneghan AF, Epstein ML, et al. (2015) Impaired Cellular Immunity in the Murine Hirschsprung’s disease (HSCR) is characterized by aganglionosis from failure of neural crest Neural Crest Conditional Deletion of Endothelin cell (NCC) migration to the distal hindgut. Up to 40% of HSCR patients suffer Hirschsprung’s- Receptor-B ’ Model of Hirschsprung s Disease. PLoS associated enterocolitis (HAEC), with an incidence that is unchanged from the pre-operative ONE 10(6): e0128822. doi:10.1371/journal. pone.0128822 to the post-operative state. Recent reports indicate that signaling pathways involved in NCC migration may also be involved in the development of secondary lymphoid organs. We hy- Academic Editor: Anatoly V. Grishin, Childrens Hospital Los Angeles, UNITED STATES pothesize that gastrointestinal (GI) mucosal immune defects occur in HSCR that may contrib- ute to enterocolitis. EdnrB was deleted from the neural crest (EdnrBNCC-/-) resulting in mutants Received: November 12, 2014 with defective NCC migration, distal colonic aganglionosis and the development of enterocoli- Accepted: May 1, 2015 tis.
    [Show full text]
  • Discovery, Characterization, and Clinical Development of the Glucagon-Like Peptides
    Discovery, characterization, and clinical development of the glucagon-like peptides Daniel J. Drucker, … , Joel F. Habener, Jens Juul Holst J Clin Invest. 2017;127(12):4217-4227. https://doi.org/10.1172/JCI97233. Harrington Prize Essay Endocrinology Gastroenterology The discovery, characterization, and clinical development of glucagon-like-peptide-1 (GLP-1) spans more than 30 years and includes contributions from multiple investigators, science recognized by the 2017 Harrington Award Prize for Innovation in Medicine. Herein, we provide perspectives on the historical events and key experimental findings establishing the biology of GLP-1 as an insulin-stimulating glucoregulatory hormone. Important attributes of GLP-1 action and enteroendocrine science are reviewed, with emphasis on mechanistic advances and clinical proof-of-concept studies. The discovery that GLP-2 promotes mucosal growth in the intestine is described, and key findings from both preclinical studies and the GLP-2 clinical development program for short bowel syndrome (SBS) are reviewed. Finally, we summarize recent progress in GLP biology, highlighting emerging concepts and scientific insights with translational relevance. Find the latest version: https://jci.me/97233/pdf The Journal of Clinical Investigation HARRINGTON PRIZE ESSAY Discovery, characterization, and clinical development of the glucagon-like peptides Daniel J. Drucker,1 Joel F. Habener,2 and Jens Juul Holst3 1Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, Ontario, Canada. 2Laboratory of Molecular Endocrinology, Massachusetts General Hospital, Harvard University, Boston, Massachusetts, USA. 3Novo Nordisk Foundation Center for Basic Metabolic Research, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark. sequences of cloned recombinant cDNA copies of messenger RNAs.
    [Show full text]
  • Β Cell Tone Is Defined by Proglucagon Peptides Through Camp Signaling
    β Cell tone is defined by proglucagon peptides through cAMP signaling Megan E. Capozzi, … , David A. D’Alessio, Jonathan E. Campbell JCI Insight. 2019;4(5):e126742. https://doi.org/10.1172/jci.insight.126742. Research Article Endocrinology Metabolism Paracrine interactions between pancreatic islet cells have been proposed as a mechanism to regulate hormone secretion and glucose homeostasis. Here, we demonstrate the importance of proglucagon-derived peptides (PGDPs) for α to β cell communication and control of insulin secretion. Signaling through this system occurs through both the glucagon-like peptide receptor (Glp1r) and glucagon receptor (Gcgr). Loss of PGDPs, or blockade of their receptors, decreases insulin secretion in response to both metabolic and nonmetabolic stimulation of mouse and human islets. This effect is due to reduced β cell cAMP and affects the quantity but not dynamics of insulin release, indicating that PGDPs dictate the magnitude of insulin output in an isolated islet. In healthy mice, additional factors that stimulate cAMP can compensate for loss of PGDP signaling; however, input from α cells is essential to maintain glucose tolerance during the metabolic stress induced by high-fat feeding. These findings demonstrate an essential role for α cell regulation of β cells, raising the possibility that abnormal paracrine signaling contributes to impaired insulin secretion in diabetes. Moreover, these findings support reconsideration of the role for α cells in postprandial glucose control. Find the latest version: https://jci.me/126742/pdf RESEARCH ARTICLE β Cell tone is defined by proglucagon peptides through cAMP signaling Megan E. Capozzi,1 Berit Svendsen,1 Sara E.
    [Show full text]
  • Edinburgh Research Explorer
    Edinburgh Research Explorer International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list Citation for published version: Davenport, AP, Alexander, SPH, Sharman, JL, Pawson, AJ, Benson, HE, Monaghan, AE, Liew, WC, Mpamhanga, CP, Bonner, TI, Neubig, RR, Pin, JP, Spedding, M & Harmar, AJ 2013, 'International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands', Pharmacological reviews, vol. 65, no. 3, pp. 967-86. https://doi.org/10.1124/pr.112.007179 Digital Object Identifier (DOI): 10.1124/pr.112.007179 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Pharmacological reviews Publisher Rights Statement: U.S. Government work not protected by U.S. copyright General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 1521-0081/65/3/967–986$25.00 http://dx.doi.org/10.1124/pr.112.007179 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:967–986, July 2013 U.S.
    [Show full text]
  • 2016 IES Annual Meeting Final Programme
    ROYAL ACADEMY OF MEDICINE IN IRELAND IRISH JOURNAL OF MEDICAL SCIENCE Irish Endocrine Society 40th Annual Meeting 14th and 15th October 2016 Stormont Hotel, Belfast Local Organiser: Doctor Hamish Courtney, REVISEDRoyal Victoria Hospital, PROOF Belfast Irish Journal of Medical Science Volume XXX Supplement X DOI 10.1007/s11845-016-1482-y 123 123 Journal : Large 11845 Dispatch : 17-8-2016 Pages : 57 Article No. : 1482 h LE h TYPESET MS Code : 1482 h44CP h DISK Ir J Med Sci Disclosure statement This supplement is paid for by the Irish Endocrine Society. However the meeting costs are supported by the following commercial sponsors: Abbott Amgen Astra Zeneca Besins Healthcare BMS Boehringer Ingleheim Consilient Ipsen Janssen-Cilag Kyowa Kirin Lilly Menarini Merck Serono MSD Novartis Novo Nordisk Pfizer Sanofi REVISED PROOF 123 Journal : Large 11845 Dispatch : 17-8-2016 Pages : 57 Article No. : 1482 h LE h TYPESET MS Code : 1482 h44CP h DISK Ir J Med Sci Novo Lecture Nordisk Lecture 1976 D.K. O’Donovan 1977 S. Bloom 1978 J.H.S. Robertson 1979 A.G. Cudworth 1980 D.A.D. Montgomery 1981 Peter Watkins 1982 G. Joplin 1983 D.R. London 1984 A.X. Bertagna 1985 Malcolm Nattrass Laurence Kennedy 1986 Brian Frier JB Ferriss 1987 Maurice Scanlon TJ McKenna 1988 D.A. Heath AB Atkinson 1989 J. Ward GH Tomkin 1990 R. Volpe KD Buchanan 1991 Michael Besser PPA Smyth 1992 R.V. Ragontte DH Hadden 1993 Bruce Weintraub David Powell 1994 Oscar Croffard Patrick Bell 1995 Robert Lindsay Brian Sheridan 1996 C.R.W. Edwards Rosemary Freaney 1997 Stephanie Amiel David McCance 1998 Robert Turner Randle Hayes 1999 Ian Hay Sean K Cunningham 2000 Stephen O’Rahilly Michael Cullen 2001 Andre Lacroix Daphne Owens 2002 J.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Development and Characterization of GLP-1 Total and Active V-PLEX
    T1530-12-77 Development and Characterization of GLP-1 Total and Active V-PLEX® Assays Priscilla Krai, Jennifer Morgan, Lalitha Janaki, Jon Buhrman, Laure Moller, Colleen Kenten, Vivek Chitnis, Seth B. Harkins, David Stewart, and Jacob N. Wohlstadter Meso Scale Discovery, Rockville, Maryland, USA CONTACT INFORMATION: [email protected] PURPOSE CALIBRATION CURVES AND SPECIFICITY ACCURACY AND PRECISION Glucagon like peptide-1 (GLP-1), an incretin hormone, is a major target of interest for researchers studying metabolic, To assess the specificity of each assay, both V-PLEX GLP-1 Total and GLP-1 Active Kits were tested for Quality control samples were prepared by spiking calibrator into non-human serum matrix at three levels (high, neurologic, and cardiovascular disorders. After post-translational processing of proglucagon, the GLP-1 peptide is LIMITS OF DETECTION nonspecific binding to the following GLP-1 metabolites and other general metabolic targets. mid, and low) within the quantitative linear range of the assay. The controls were measured using a minimum of secreted in its bioactive form, which binds a specific receptor (GLP-1R) to stimulate insulin release. Once in circulation, Cross-reactivity at or below 0.02% is reported as not detected (ND). three replicates tested over multiple days and multiple operators for a total of at least 36 runs. The accuracy of The figure below demonstrates typical calibration curves for the analytes in the V-PLEX GLP-1 Total and however, the peptide is rapidly cleaved by proteases (e.g. DPP-IV), yielding several other metabolites that account for *Although weakly cross-reactive, Liraglutide and GLP-1 have nearly identical sequences and have the control determinations fell within 20% of the expected concentration with precision of less than 20% CV in the GLP-1 Active Kits.
    [Show full text]
  • Lessons from Single and Double Incretin Receptor Knockout Mice
    Regulatory Peptides 128 (2005) 125–134 www.elsevier.com/locate/regpep Review GIP and GLP-1 as incretin hormones: Lessons from single and double incretin receptor knockout mice Tanya Hansotia, Daniel J. Drucker* Department of Medicine, Banting and Best Diabetes Centre, Toronto General Hospital, and the University of Toronto, 200 Elizabeth Street MBRW4R-402, Toronto, Ontario, Canada M5G 2C4 Received 6 July 2004; received in revised form 8 July 2004; accepted 15 July 2004 Available online 25 August 2004 Abstract Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are gut-derived incretins secreted in response to nutrient ingestion. Both incretins potentiate glucose-dependent insulin secretion and enhance h-cell mass through regulation of h-cell proliferation, neogenesis and apoptosis. In contrast, GLP-1, but not GIP, inhibits gastric emptying, glucagon secretion, and food intake. Furthermore, human subjects with Type 2 diabetes exhibit relative resistance to the actions of GIP, but not GLP-1R agonists. The physiological importance of both incretins has been investigated through generation and analysis of incretin receptor knockout mice. Elimination of incretin receptor action in GIPRÀ/À or GLP-1RÀ/À mice produces only modest impairment in glucose homeostasis. Similarly, double incretin receptor knockout (DIRKO) mice exhibit normal body weight and normal levels of plasma glucagon and hypoglycemic responses to exogenous insulin. However, glucose-stimulated insulin secretion is significantly decreased following oral but not intraperitoneal glucose challenge in DIRKO mice and the glucose lowering actions of dipeptidyl peptidase-IV (DPP-IV) inhibitors are extinguished in DIRKO mice. Hence, incretin receptor signaling exerts physiologically relevant actions critical for glucose homeostasis, and represents a pharmacologically attractive target for development of agents for the treatment of Type 2 diabetes.
    [Show full text]
  • University of Groningen Genetics Dissection and Functional
    University of Groningen Genetics dissection and functional studies in Hirschsprung disease Sribudiani, Yunia IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2011 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Sribudiani, Y. (2011). Genetics dissection and functional studies in Hirschsprung disease Groningen: s.n. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 11-02-2018 Genetic Dissection and Functional Studies in Hirschsprung Disease Yunia Sribudiani Genetic Dissection and Functional Studies in Hirschsprung Disease Y. Sribudiani PhD Thesis – Department of Genetics University Medical Center Groningen, University of Groningen Groningen, the Netherlands This study was financially supported by University of Groningen and Research Institute GUIDE. ISBN/EAN: 978-94-6182-039-6 Cover Ilustration: Ella Elviana, www.ellasworks.blogspot.com Cover & book layout: Briyan B Hendro, www.brianos.daportfolio.com Printed by: Off Page, Amsterdam, www.offpage.nl Printing of this thesis was financially supported by: University of Groningen, GUIDE and Department of Genetics - UMCG.
    [Show full text]
  • G-Protein Coupled Receptors in Lipid Rafts and Caveolae: How, When and Why Do They Go There?
    325 G-protein coupled receptors in lipid rafts and caveolae: how, when and why do they go there? B Chini and M Parenti1 CNR Institute of Neuroscience, Cellular and Molecular Pharmacology Section, Milan, Italy 1Department of Experimental and Environmental Medicine and Medical Biotechnologies, University of Milano-Bicocca, Monza, Italy (Requests for offprints should be addressed to B Chini; Email: [email protected]) Abstract This review describes the advances in our understanding of the role of G-protein coupled receptor (GPCR) localisation in membrane microdomains known as lipid rafts and caveolae. The growing interest in these specialised regions is due to the recognition that they are involved in the regulation of a number of cell functions, including the fine-tuning of various signalling molecules. As a number of GPCRs have been found to be enriched in lipid rafts and/or caveolae by means of different experimental approaches, we first discuss the pitfalls and uncertainties related to the use of these different procedures. We then analyse the addressing signals that drive and/or stabilise GPCRs in lipid rafts and caveolae, and explore the role of rafts/caveolae in regulating GPCR trafficking, particularly in receptor exo- and endocytosis. Finally, we review the growing evidence that lipid rafts and caveolae participate in the regulation of GPCR signalling by affecting both signalling selectivity and coupling efficacy. Journal of Molecular Endocrinology (2004) 32, 325–338 Introduction cascade (Dykstra et al. 2001, Sedwick & Altman 2002, Werlen & Palmer 2002), unravelling the role Lipid rafts and caveolae have been found to be of rafts and caveolae in the functional regulation of involved in the regulation of various cell functions, other signalling components is still at its very including the homeostasis of cholesterol (Ikonen & beginning.
    [Show full text]
  • Synaptamide Activates the Adhesion GPCR GPR110 (ADGRF1) Through GAIN Domain Binding
    ARTICLE https://doi.org/10.1038/s42003-020-0831-6 OPEN Synaptamide activates the adhesion GPCR GPR110 (ADGRF1) through GAIN domain binding Bill X. Huang1, Xin Hu2, Heung-Sun Kwon1, Cheng Fu1, Ji-Won Lee1, Noel Southall2, Juan Marugan2 & ✉ Hee-Yong Kim1 1234567890():,; Adhesion G protein-coupled receptors (aGPCR) are characterized by a large extracellular region containing a conserved GPCR-autoproteolysis-inducing (GAIN) domain. Despite their relevance to several disease conditions, we do not understand the molecular mechanism by which aGPCRs are physiologically activated. GPR110 (ADGRF1) was recently deorphanized as the functional receptor of N-docosahexaenoylethanolamine (synaptamide), a potent synap- togenic metabolite of docosahexaenoic acid. Thus far, synaptamide is the first and only small- molecule endogenous ligand of an aGPCR. Here, we demonstrate the molecular basis of synaptamide-induced activation of GPR110 in living cells. Using in-cell chemical cross-linking/ mass spectrometry, computational modeling and mutagenesis-assisted functional assays, we discover that synaptamide specifically binds to the interface of GPR110 GAIN subdomains through interactions with residues Q511, N512 and Y513, causing an intracellular conforma- tional change near TM6 that triggers downstream signaling. This ligand-induced GAIN-tar- geted activation mechanism provides a framework for understanding the physiological function of aGPCRs and therapeutic targeting in the GAIN domain. 1 Laboratory of Molecular Signaling, National Institute on Alcohol Abuse
    [Show full text]